Strong momentum in the global specialty pipeline continues to support SUNPHARMA.NS. Regulatory approvals in dermatology and ophthalmology segments are cushioning generic pricing headwinds in the US market. The numbers look interesting across domestic formulations as well. Not advice, DYOR.
No replies yet.